ClinicalTrials.gg
CompletedNCT02254304PROCEEDUpdated Mar 30, 2018Results posted

Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™

A Phase 4 interventional study of Rebif in Relapsing Multiple Sclerosis and Clinically Isolated Syndrome, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-03-30.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
106
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies testing Interferon beta-1a in Multiple Sclerosis — none open to participants now, none under way, none of them phase 3. Interferon beta-1a · Multiple Sclerosis.

Enrollment
14th of 34
106 · median 85
Started
2014
with 2 others
Phase 4
15 of 34
none open now
Registered
32nd of 34
by date
Lead sponsor
6 of 34
Merck KGaA, Darmstadt, Germany

Among the 34 studies testing Interferon beta-1a in Multiple Sclerosis, this one is the 14th largest by enrollment, is one of 3 that started in 2014, is one of 15 in phase 4, and was the 32nd registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

None of the 34 studies testing Interferon beta-1a in Multiple Sclerosis is open now. The open studies under Multiple Sclerosis, anywhere →

About Interferon beta-1a

Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 34 studies testing Interferon beta-1a in Multiple Sclerosis as a file.
02

Study summary

This is a Phase 4, interventional, multicenter study of subcutaneous Rebif® (interferon beta-1a) using RebiSmart™ device to assess effectiveness and adherence of treatment in subjects with clinically isolated syndrome (CIS) or relapsing multiple sclerosis (RMS).

03

Conditions studied

  • Relapsing Multiple Sclerosis
  • Clinically Isolated Syndrome

Browse trials for

Keywords

  • Relapsing multiple sclerosis
  • Clinically isolated syndrome
  • RMS
  • CIS
  • RebiSmart™
  • Rebif®
  • Interferon beta-1a
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects between 18 to 65 years of age
  • Female subjects must be neither pregnant nor breast-feeding and must lack as defined in the protocol
  • Subjects diagnosed with CIS or RMS according to the revised McDonald criteria (2010)
  • Treatment-naive subjects or subjects treated with Rebif® multi-dose injected by RebiSmart™ for no longer than 6 weeks prior to Baseline visit
  • Subjects that are able to self-inject with RebiSmart™ (in the opinion of the physician)
  • Subjects with Expanded Disability Status Scale (EDSS) score less than (\<) 6 (inclusive) at Baseline
  • Signed and subject data collection form

Exclusion criteria

Exclusion Criteria:

  • Subjects experiencing a relapse within 30 days before Baseline
  • Participation in other studies within 30 days before Baseline
  • Received any MS therapy within 6 months prior to study enrolment (for example, other disease-modifying drugs: immunomodulatory, agents or combination therapy) with the exception of Rebif® multi-dose injected by RebiSmart™
  • Any visual or physical impairment that precludes the subject from self-injecting the treatment using the RebiSmart™
  • Pregnancy and breast-feeding
  • Serious or acute heart disease such as uncontrolled cardiac dysrhythmias, uncontrolled angina pectoris, cardiomyopathy, or uncontrolled congestive heart failure, as per investigator opinion
  • Current or past (within the last 2 years) history of alcohol or drug abuse
  • Have any to treatment with interferon beta-1a according to Summary of Product Characteristics
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    Rebif in Relapsing Multiple Sclerosis (RMS) Subjects

    Drug: Rebif

  • Experimental
    Rebif in Clinically Isolated Syndromes (CIS) Subjects

    Drug: Rebif

Interventions

  • DrugRebif

    Rebif will be administered at a dose of 44 microgram (mcg) subcutaneously using RebiSmart auto-injector three times a week for a total duration up to 12 months.

    Also known as: Interferon beta-1a

06

What researchers measure

Primary outcomes

  1. Percentage of Relapse-free RMS Subjects

    A relapse was defined as the appearance of a new symptom or worsening of an old symptom, attributable to multiple sclerosis (MS), accompanied by an appropriate new neurological abnormality or focal neurological dysfunction lasting at least 24 hours in the absence of fever, and preceded by stability or improvement for at least 30 days. Relapse-free RMS subjects were those who did not had relapse during 12 month treatment period. Data was planned to be reported for "Rebif in RMS Subjects" arm.

    Time frame: Month 12

  2. Time to the First Relapse for CIS Subjects

    A relapse was defined as the appearance of a new symptom or worsening of an old symptom, attributable to MS, accompanied by an appropriate new neurological abnormality or focal neurological dysfunction lasting at least 24 hours in the absence of fever, and preceded by stability or improvement for at least 30 days. Time to the first relapse was defined as the duration from start of the treatment until first relapse. Data was planned to be reported for "Rebif in CIS Subjects" arm.

    Time frame: Baseline up to 12 months

Secondary outcomes

  1. Percentage of Subjects With Treatment Adherence

    According to the World Health Organisation (WHO), treatment adherence is defined as both compliance (taking the medication in the correct dose and according to the schedule prescribed) and persistency (maintenance of the drug regimen over the long-term). Percentage of subjects with treatment adherence under different categories (\<=50%, \>50-75%, \>75-90%, \>90%) were presented.

    Time frame: Month 12

  2. Percentage of Subjects With Relapse by Adherence Category

    A relapse was defined as the appearance of a new symptom or worsening of an old symptom, attributable to multiple sclerosis (MS), accompanied by an appropriate new neurological abnormality or focal neurological dysfunction lasting at least 24 hours in the absence of fever, and preceded by stability or improvement for at least 30 days. According to the World Health Organisation (WHO), treatment adherence is defined as both compliance (taking the medication in the correct dose and according to the schedule prescribed) and persistency (maintenance of the drug regimen over the long-term). Percentage of subjects with relapses by adherence categories (\<=50%, \>50-75%, \>75-90%, \>90%) were presented. Adherence missing are the subjects who withdrew before 12 months and who did not have any relapses before withdrawal.

    Time frame: Month 12

  3. Percentage of Subjects Who Prematurely Terminated Treatment and Reasons

    Percentage of subjects who prematurely terminated treatment and reasons were presented.

    Time frame: Baseline up to 12 months

  4. Percentage of Subjects Free From Clinical Disease Activity

    Expanded Disability Status Scale is abbreviated as EDSS.

    Time frame: Baseline up to 12 months

  5. Percentage of Subjects Free From Disability Progression

    Expanded Disability Status Scale is abbreviated as EDSS.

    Time frame: Baseline up to 12 months

  6. Mean Number of Relapses in RMS Subjects

    A relapse was defined as the appearance of a new symptom or worsening of an old symptom, attributable to multiple sclerosis (MS), accompanied by an appropriate new neurological abnormality or focal neurological dysfunction lasting at least 24 hours in the absence of fever, and preceded by stability or improvement for at least 30 days.

    Time frame: Month 12

  7. Number of Subjects With Reasons of Missed Injections

    Number of subjects with the reasons of missed injections were presented. Aspartate transaminase and alanine transaminase are abbreviated as ALT and AST respectively. Glutamic oxaloacetic transaminase and glutamic pyruvic transaminase are abbreviated as GOT and GPT respectively.

    Time frame: Baseline up to 12 months

  8. Overall Evaluation of RebiSmart Use as Assessed by Investigator

    Evaluation of RebiSmart was categorized under very easy, quite easy, Neither easy nor difficult, very difficult and missing

    Time frame: Month 12

  9. Healthcare Resource Utilization Questionnaire - Number of Visits to Clinic by Subjects Due to Multiple Sclerosis (MS)

    Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Number of visits to clinic by subjects due to MS were presented.

    Time frame: Month 12

  10. Healthcare Resource Utilization Questionnaire - Number of Subjects Visiting Different Types of Doctors During Their Clinical Visit

    Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Subjects who took consultations with specialists, general practitioners for MS were presented.

    Time frame: Month 12

  11. Healthcare Resource Utilization Questionnaire - Number of Visits by Healthcare Professional to Subjects' Home

    Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Number of visits by healthcare professional to subjects' home were presented.

    Time frame: Month 12

  12. Healthcare Resource Utilization Questionnaire - Number of Times Subjects Visited Emergency Room Due to Multiple Sclerosis (MS)

    Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Number of times subjects visited emergency room due to MS were presented.

    Time frame: Month 12

  13. Healthcare Resource Utilization Questionnaire - Number of Days Subjects Hospitalized Due to Multiple Sclerosis (MS)

    Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Number of days subjects hospitalized due to MS were presented.

    Time frame: Month 12

  14. Healthcare Resource Utilization Questionnaire -Number of Subjects Who Paid Someone to Assist Them Due to Multiple Sclerosis (MS)

    Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Number of subjects who paid someone to assist them due to MS were presented.

    Time frame: Month 12

  15. Healthcare Resource Utilization Questionnaire - Number of Days Per Week Assistant Worked For Subject Due to Multiple Sclerosis (MS)

    Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Number of days per week assistant worked for subject due to MS were presented.

    Time frame: Month 12

  16. Healthcare Resource Utilization Questionnaire - Number of Hours Per Day Assistant Worked for Subject Due to Multiple Sclerosis (MS)

    Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Number of hours per week assistant worked for subject due to MS were presented.

    Time frame: Month 12

  17. Healthcare Resource Utilization Questionnaire - Number of Subjects Whose Relatives or Friends Missed Work Due to Subjects' Multiple Sclerosis (MS)

    Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Number of subjects whose relatives or friends missed work due to subjects' MS were presented.

    Time frame: Month 12

  18. Healthcare Resource Utilization Questionnaire - Number of Working Days Missed by Relative or Friend Due to Subjects' Multiple Sclerosis (MS)

    Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Number of working days missed by relative or friend due to subjects' MS were presented.

    Time frame: Month 12

  19. Healthcare Resource Utilization Questionnaire - Number of Subjects Who Missed Any Full Days From Work Due to Multiple Sclerosis (MS).

    Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Number of subjects who missed any full days from work due to MS were presented.

    Time frame: Month 12

  20. Healthcare Resource Utilization Questionnaire - Number of Full Days Missed From Work by Subjects

    Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Number of full days missed from work by subjects were presented.

    Time frame: Month 12

  21. Healthcare Resource Utilization Questionnaire - Number of Subjects Who Missed Any Partial Days From Work Due to Multiple Sclerosis (MS).

    Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Number of subjects who missed any partial days from work due to MS were presented.

    Time frame: Month 12

  22. Healthcare Resource Utilization Questionnaire - Number of Hours Per Day Missed From Work by Subjects

    Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Number of hours per day missed from work by subjects were presented.

    Time frame: Month 12

  23. Healthcare Resource Utilization Questionnaire - Number of Subjects Accomplished Less Work Due to Multiple Sclerosis (MS)

    Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Number of subjects accomplished less work due to MS were presented.

    Time frame: Month 12

  24. Healthcare Resource Utilization Questionnaire - Number of Subjects With Percentage of Work Completed Despite of Multiple Sclerosis (MS)

    Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Amount of work done by subjects in spite of multiple sclerosis was presented under different percentages (0-100%)

    Time frame: Month 12

  25. Number of Subjects With Medication Adherence Based on Morisky Medication Adherence Score

    The Morisky Medication Adherence Scale (MMAS) is a valid and reliable instrument that consists of 8 items that measure medication adherence. The scores of the MMAS-8 range from 0 to 8. This self-report scale consists of 7 items answered with a yes or no and 1 item with a 5-point Likert scale. A score below 6 indicates low adherence, a score between 6 to \< 8 indicates medium adherence and a score of 8 indicates high adherence.

    Time frame: Month 12

  26. Number of Subjects With Adverse Event or Adverse Drug Reaction (AE/ADR), Serious AE/ADR, AE/ADR Leading to Death and AE/ADR Leading to Early Termination

    An AE was any untoward medical occurrence in a subject or clinical investigation in a subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An ADR was any unfavourable or unintended response (adverse event) that could possibly be related to drug treatment. An SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. AE/ADR was planned to be reported for both the arms together.

    Time frame: Baseline up to 12 months

  27. Expanded Disability Status Scale (EDSS) Score

    EDSS is an ordinal scale in half-point increments that qualifies disability in participants with MS. It consists of 8 ordinal rating scales assessing seven functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder and cerebral) as well as ambulation. EDSS total score ranges from 0 (normal neurological examination) to 10 (death due to MS).

    Time frame: Baseline, Month 12

  28. Body Mass Index (BMI)

    BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2).

    Time frame: Baseline, Month 12

07

Results

Posted Mar 30, 2018

Participant flow

The study was conducted at 7 sites in Romania.

Participant flow — Overall Study
MilestoneRebif In RMS SubjectsRebif in CIS Subjects
Started8917
Completed7513
Not completed144
Withdrew: Adverse event21
Withdrew: Lost to follow-up22
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject30
Withdrew: Injection site pain and injection fear10
Withdrew: Personal causes41
Withdrew: Personal decision10

Outcome measures

PrimaryPercentage of Relapse-free RMS Subjects

A relapse was defined as the appearance of a new symptom or worsening of an old symptom, attributable to multiple sclerosis (MS), accompanied by an appropriate new neurological abnormality or focal neurological dysfunction lasting at least 24 hours in the absence of fever, and preceded by stability or improvement for at least 30 days. Relapse-free RMS subjects were those who did not had relapse during 12 month treatment period. Data was planned to be reported for "Rebif in RMS Subjects" arm.

Time frame:
Month 12
Reported as:
Number · percentage of subjects
Percentage of Relapse-free RMS Subjects
percentage of subjectsRebif In RMS Subjects
Percentage of Relapse-free RMS Subjects66.3
PrimaryTime to the First Relapse for CIS Subjects

A relapse was defined as the appearance of a new symptom or worsening of an old symptom, attributable to MS, accompanied by an appropriate new neurological abnormality or focal neurological dysfunction lasting at least 24 hours in the absence of fever, and preceded by stability or improvement for at least 30 days. Time to the first relapse was defined as the duration from start of the treatment until first relapse. Data was planned to be reported for "Rebif in CIS Subjects" arm.

Time frame:
Baseline up to 12 months
Reported as:
Median · months
Time to the First Relapse for CIS Subjects
monthsRebif in CIS Subjects
Time to the First Relapse for CIS SubjectsNA (NA to NA)
SecondaryPercentage of Subjects With Treatment Adherence

According to the World Health Organisation (WHO), treatment adherence is defined as both compliance (taking the medication in the correct dose and according to the schedule prescribed) and persistency (maintenance of the drug regimen over the long-term). Percentage of subjects with treatment adherence under different categories (\<=50%, \>50-75%, \>75-90%, \>90%) were presented.

Time frame:
Month 12
Reported as:
Number · percentage of subjects
Percentage of Subjects With Treatment Adherence
percentage of subjectsRebif In RMS SubjectsRebif in CIS Subjects
Adherence <=50%2.211.8
Adherence >50-75%2.20.0
Adherence >75-90%13.50.0
Adherence >90%80.988.2
Missing1.10.0
SecondaryPercentage of Subjects With Relapse by Adherence Category

A relapse was defined as the appearance of a new symptom or worsening of an old symptom, attributable to multiple sclerosis (MS), accompanied by an appropriate new neurological abnormality or focal neurological dysfunction lasting at least 24 hours in the absence of fever, and preceded by stability or improvement for at least 30 days. According to the World Health Organisation (WHO), treatment adherence is defined as both compliance (taking the medication in the correct dose and according to the schedule prescribed) and persistency (maintenance of the drug regimen over the long-term). Percentage of subjects with relapses by adherence categories (\<=50%, \>50-75%, \>75-90%, \>90%) were presented. Adherence missing are the subjects who withdrew before 12 months and who did not have any relapses before withdrawal.

Time frame:
Month 12
Reported as:
Number · percentage of subjects
Percentage of Subjects With Relapse by Adherence Category
percentage of subjectsRebif In RMS SubjectsRebif in CIS Subjects
Relapse Status Yes, Adherence <= 50%0.00.0
Relapse Status Yes, Adherence >50-75%0.0—
Relapse Status Yes, Adherence >75-90%16.7—
Relapse Status Yes, Adherence >90%19.46.7
Relapse Status Yes, Adherence Missing0.0—
Relapse Status No, Adherence <= 50%0.050.0
Relapse Status No, Adherence >50-75%50.0—
Relapse Status No, Adherence >75-90%50.0—
Relapse Status No, Adherence >90%72.273.3
Relapse Status No, Adherence Missing0.0—
Relapse Status Missing, Adherence <=50%100.050.0
Relapse Status Missing, Adherence >50-75%50.0—
Relapse Status Missing, Adherence >75-90%33.30.0
Relapse Status Missing, Adherence >90%8.320.0
Relapse Status Missing, Adherence Missing100.0—
SecondaryPercentage of Subjects Who Prematurely Terminated Treatment and Reasons

Percentage of subjects who prematurely terminated treatment and reasons were presented.

Time frame:
Baseline up to 12 months
Reported as:
Number · percentage of subjects
Percentage of Subjects Who Prematurely Terminated Treatment and Reasons
percentage of subjectsRebif In RMS SubjectsRebif in CIS Subjects
Adverse Event2.25.9
Lost to follow-up2.211.8
Protocol Non-compliance1.10.0
Withdrew Consent3.40.0
Pain at Injection site and fear of Injection1.10.0
Personal causes4.55.9
Personal decision1.10.0
SecondaryPercentage of Subjects Free From Clinical Disease Activity

Expanded Disability Status Scale is abbreviated as EDSS.

Time frame:
Baseline up to 12 months

No measurements were reported for this outcome.

SecondaryPercentage of Subjects Free From Disability Progression

Expanded Disability Status Scale is abbreviated as EDSS.

Time frame:
Baseline up to 12 months

No measurements were reported for this outcome.

SecondaryMean Number of Relapses in RMS Subjects

A relapse was defined as the appearance of a new symptom or worsening of an old symptom, attributable to multiple sclerosis (MS), accompanied by an appropriate new neurological abnormality or focal neurological dysfunction lasting at least 24 hours in the absence of fever, and preceded by stability or improvement for at least 30 days.

Time frame:
Month 12
Reported as:
Mean · relapses
Mean Number of Relapses in RMS Subjects
relapsesRebif In RMS Subjects
Mean Number of Relapses in RMS Subjects0.2 ± 0.54
SecondaryNumber of Subjects With Reasons of Missed Injections

Number of subjects with the reasons of missed injections were presented. Aspartate transaminase and alanine transaminase are abbreviated as ALT and AST respectively. Glutamic oxaloacetic transaminase and glutamic pyruvic transaminase are abbreviated as GOT and GPT respectively.

Time frame:
Baseline up to 12 months
Reported as:
Number · subjects
Number of Subjects With Reasons of Missed Injections
subjectsRebif In RMS and CIS Subjects
Forgot to Injection48
Tired23
Fear of Injection11
Did not want to have Injection5
Pain at Injection site5
Flu-like symptoms4
Adverse event2
Device broken1
Device malfunctions1
Device not functioning1
Difficulty using the device1
Elevated ALT and AST1
Elevated liver enzymes2
Increased GOT and GPT levels2
Local erythema and induration1
Missed study medication1
Forgot the device at home1
No access to medication1
could not came at the scheduled visit1
Patient redrawn intracutaneous1
Stop the treatment1
Technical problems with Rebismart1
SecondaryOverall Evaluation of RebiSmart Use as Assessed by Investigator

Evaluation of RebiSmart was categorized under very easy, quite easy, Neither easy nor difficult, very difficult and missing

Time frame:
Month 12
Reported as:
Number · subjects
Overall Evaluation of RebiSmart Use as Assessed by Investigator
subjectsRebif In RMS SubjectsRebif in CIS Subjects
Very easy4613
Quite easy321
Neither easy nor difficult91
Quite difficult00
Very difficult12
Missing10
SecondaryHealthcare Resource Utilization Questionnaire - Number of Visits to Clinic by Subjects Due to Multiple Sclerosis (MS)

Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Number of visits to clinic by subjects due to MS were presented.

Time frame:
Month 12
Reported as:
Mean · visits
Healthcare Resource Utilization Questionnaire - Number of Visits to Clinic by Subjects Due to Multiple Sclerosis (MS)
visitsRebif In RMS SubjectsRebif in CIS Subjects
Healthcare Resource Utilization Questionnaire - Number of Visits to Clinic by Subjects Due to Multiple Sclerosis (MS)0.2 ± 0.490.1 ± 0.49
SecondaryHealthcare Resource Utilization Questionnaire - Number of Subjects Visiting Different Types of Doctors During Their Clinical Visit

Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Subjects who took consultations with specialists, general practitioners for MS were presented.

Time frame:
Month 12
Reported as:
Number · subjects
Healthcare Resource Utilization Questionnaire - Number of Subjects Visiting Different Types of Doctors During Their Clinical Visit
subjectsRebif In RMS SubjectsRebif in CIS Subjects
General practitioner1 ± 0.491 ± 0.49
Specialist150
SecondaryHealthcare Resource Utilization Questionnaire - Number of Visits by Healthcare Professional to Subjects' Home

Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Number of visits by healthcare professional to subjects' home were presented.

Time frame:
Month 12
Reported as:
Mean · visits
Healthcare Resource Utilization Questionnaire - Number of Visits by Healthcare Professional to Subjects' Home
visitsRebif In RMS SubjectsRebif in CIS Subjects
Healthcare Resource Utilization Questionnaire - Number of Visits by Healthcare Professional to Subjects' Home0.0 ± 0.110.0 ± 0.00
SecondaryHealthcare Resource Utilization Questionnaire - Number of Times Subjects Visited Emergency Room Due to Multiple Sclerosis (MS)

Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Number of times subjects visited emergency room due to MS were presented.

Time frame:
Month 12
Reported as:
Mean · emergency room visits
Healthcare Resource Utilization Questionnaire - Number of Times Subjects Visited Emergency Room Due to Multiple Sclerosis (MS)
emergency room visitsRebif In RMS SubjectsRebif in CIS Subjects
Healthcare Resource Utilization Questionnaire - Number of Times Subjects Visited Emergency Room Due to Multiple Sclerosis (MS)0.0 ± 0.000.0 ± 0.00
SecondaryHealthcare Resource Utilization Questionnaire - Number of Days Subjects Hospitalized Due to Multiple Sclerosis (MS)

Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Number of days subjects hospitalized due to MS were presented.

Time frame:
Month 12
Reported as:
Mean · days
Healthcare Resource Utilization Questionnaire - Number of Days Subjects Hospitalized Due to Multiple Sclerosis (MS)
daysRebif In RMS SubjectsRebif in CIS Subjects
Healthcare Resource Utilization Questionnaire - Number of Days Subjects Hospitalized Due to Multiple Sclerosis (MS)0.1 ± 0.750.0 ± 0.00
SecondaryHealthcare Resource Utilization Questionnaire -Number of Subjects Who Paid Someone to Assist Them Due to Multiple Sclerosis (MS)

Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Number of subjects who paid someone to assist them due to MS were presented.

Time frame:
Month 12
Reported as:
Number · subjects
Healthcare Resource Utilization Questionnaire -Number of Subjects Who Paid Someone to Assist Them Due to Multiple Sclerosis (MS)
subjectsRebif In RMS SubjectsRebif in CIS Subjects
Healthcare Resource Utilization Questionnaire -Number of Subjects Who Paid Someone to Assist Them Due to Multiple Sclerosis (MS)2 ± 0.751 ± 0.00
SecondaryHealthcare Resource Utilization Questionnaire - Number of Days Per Week Assistant Worked For Subject Due to Multiple Sclerosis (MS)

Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Number of days per week assistant worked for subject due to MS were presented.

Time frame:
Month 12
Reported as:
Mean · days per week
Healthcare Resource Utilization Questionnaire - Number of Days Per Week Assistant Worked For Subject Due to Multiple Sclerosis (MS)
days per weekRebif In RMS SubjectsRebif in CIS Subjects
Healthcare Resource Utilization Questionnaire - Number of Days Per Week Assistant Worked For Subject Due to Multiple Sclerosis (MS)2.5 ± 2.122.0 ± NA
SecondaryHealthcare Resource Utilization Questionnaire - Number of Hours Per Day Assistant Worked for Subject Due to Multiple Sclerosis (MS)

Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Number of hours per week assistant worked for subject due to MS were presented.

Time frame:
Month 12
Reported as:
Mean · hours per day
Healthcare Resource Utilization Questionnaire - Number of Hours Per Day Assistant Worked for Subject Due to Multiple Sclerosis (MS)
hours per dayRebif In RMS SubjectsRebif in CIS Subjects
Healthcare Resource Utilization Questionnaire - Number of Hours Per Day Assistant Worked for Subject Due to Multiple Sclerosis (MS)2.0 ± 1.414.0 ± NA
SecondaryHealthcare Resource Utilization Questionnaire - Number of Subjects Whose Relatives or Friends Missed Work Due to Subjects' Multiple Sclerosis (MS)

Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Number of subjects whose relatives or friends missed work due to subjects' MS were presented.

Time frame:
Month 12
Reported as:
Number · subject
Healthcare Resource Utilization Questionnaire - Number of Subjects Whose Relatives or Friends Missed Work Due to Subjects' Multiple Sclerosis (MS)
subjectRebif In RMS SubjectsRebif in CIS Subjects
Healthcare Resource Utilization Questionnaire - Number of Subjects Whose Relatives or Friends Missed Work Due to Subjects' Multiple Sclerosis (MS)1 ± 1.411 ± NA
SecondaryHealthcare Resource Utilization Questionnaire - Number of Working Days Missed by Relative or Friend Due to Subjects' Multiple Sclerosis (MS)

Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Number of working days missed by relative or friend due to subjects' MS were presented.

Time frame:
Month 12
Reported as:
Mean · days
Healthcare Resource Utilization Questionnaire - Number of Working Days Missed by Relative or Friend Due to Subjects' Multiple Sclerosis (MS)
daysRebif In RMS SubjectsRebif in CIS Subjects
Healthcare Resource Utilization Questionnaire - Number of Working Days Missed by Relative or Friend Due to Subjects' Multiple Sclerosis (MS)1 ± NA3 ± NA
SecondaryHealthcare Resource Utilization Questionnaire - Number of Subjects Who Missed Any Full Days From Work Due to Multiple Sclerosis (MS).

Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Number of subjects who missed any full days from work due to MS were presented.

Time frame:
Month 12
Reported as:
Number · subjects
Healthcare Resource Utilization Questionnaire - Number of Subjects Who Missed Any Full Days From Work Due to Multiple Sclerosis (MS).
subjectsRebif In RMS SubjectsRebif in CIS Subjects
Healthcare Resource Utilization Questionnaire - Number of Subjects Who Missed Any Full Days From Work Due to Multiple Sclerosis (MS).2 ± 1.412 ± NA
SecondaryHealthcare Resource Utilization Questionnaire - Number of Full Days Missed From Work by Subjects

Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Number of full days missed from work by subjects were presented.

Time frame:
Month 12
Reported as:
Mean · days
Healthcare Resource Utilization Questionnaire - Number of Full Days Missed From Work by Subjects
daysRebif In RMS SubjectsRebif in CIS Subjects
Healthcare Resource Utilization Questionnaire - Number of Full Days Missed From Work by Subjects46.5 ± 61.523.5 ± 2.12
SecondaryHealthcare Resource Utilization Questionnaire - Number of Subjects Who Missed Any Partial Days From Work Due to Multiple Sclerosis (MS).

Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Number of subjects who missed any partial days from work due to MS were presented.

Time frame:
Month 12
Reported as:
Number · subjects
Healthcare Resource Utilization Questionnaire - Number of Subjects Who Missed Any Partial Days From Work Due to Multiple Sclerosis (MS).
subjectsRebif In RMS SubjectsRebif in CIS Subjects
Healthcare Resource Utilization Questionnaire - Number of Subjects Who Missed Any Partial Days From Work Due to Multiple Sclerosis (MS).1 ± 1.412 ± NA
SecondaryHealthcare Resource Utilization Questionnaire - Number of Hours Per Day Missed From Work by Subjects

Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Number of hours per day missed from work by subjects were presented.

Time frame:
Month 12
Reported as:
Mean · hours per day
Healthcare Resource Utilization Questionnaire - Number of Hours Per Day Missed From Work by Subjects
hours per dayRebif In RMS SubjectsRebif in CIS Subjects
Healthcare Resource Utilization Questionnaire - Number of Hours Per Day Missed From Work by Subjects8.0 ± NA3.0 ± 2.83
SecondaryHealthcare Resource Utilization Questionnaire - Number of Subjects Accomplished Less Work Due to Multiple Sclerosis (MS)

Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Number of subjects accomplished less work due to MS were presented.

Time frame:
Month 12
Reported as:
Number · subjects
Healthcare Resource Utilization Questionnaire - Number of Subjects Accomplished Less Work Due to Multiple Sclerosis (MS)
subjectsRebif In RMS SubjectsRebif in CIS Subjects
Healthcare Resource Utilization Questionnaire - Number of Subjects Accomplished Less Work Due to Multiple Sclerosis (MS)7 ± NA1 ± 2.83
SecondaryHealthcare Resource Utilization Questionnaire - Number of Subjects With Percentage of Work Completed Despite of Multiple Sclerosis (MS)

Subjects was assessed at Month 12 utilizing the Health Resource Utilization Questionnaire (HRUQ), a subject self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilization was collected in the following areas: admissions and stays in the hospital, emergency room, consultations with specialists, general practitioners, or other healthcare professionals, work productivity, health care financial impact. Amount of work done by subjects in spite of multiple sclerosis was presented under different percentages (0-100%)

Time frame:
Month 12
Reported as:
Number · Subjects
Healthcare Resource Utilization Questionnaire - Number of Subjects With Percentage of Work Completed Despite of Multiple Sclerosis (MS)
SubjectsRebif In RMS SubjectsRebif in CIS Subjects
0% Work Completed0 ± NA0 ± 2.83
10% Work Completed10
20% Work Completed00
30% Work Completed10
40% Work Completed00
50% Work Completed00
60% Work Completed00
70% Work Completed00
80% Work Completed31
90% Work Completed20
100% Work Completed00
SecondaryNumber of Subjects With Medication Adherence Based on Morisky Medication Adherence Score

The Morisky Medication Adherence Scale (MMAS) is a valid and reliable instrument that consists of 8 items that measure medication adherence. The scores of the MMAS-8 range from 0 to 8. This self-report scale consists of 7 items answered with a yes or no and 1 item with a 5-point Likert scale. A score below 6 indicates low adherence, a score between 6 to \< 8 indicates medium adherence and a score of 8 indicates high adherence.

Time frame:
Month 12
Reported as:
Number · subjects
Number of Subjects With Medication Adherence Based on Morisky Medication Adherence Score
subjectsRebif In RMS SubjectsRebif in CIS Subjects
Low Adherence233
Medium Adherence456
High Adherence218
SecondaryNumber of Subjects With Adverse Event or Adverse Drug Reaction (AE/ADR), Serious AE/ADR, AE/ADR Leading to Death and AE/ADR Leading to Early Termination

An AE was any untoward medical occurrence in a subject or clinical investigation in a subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An ADR was any unfavourable or unintended response (adverse event) that could possibly be related to drug treatment. An SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. AE/ADR was planned to be reported for both the arms together.

Time frame:
Baseline up to 12 months
Reported as:
Number · subjects
Number of Subjects With Adverse Event or Adverse Drug Reaction (AE/ADR), Serious AE/ADR, AE/ADR Leading to Death and AE/ADR Leading to Early Termination
subjectsRebif
AE/ADR30
Serious AE/ADR1
AE/ADR Leading to Death0
AE/ADR Leading to Early Termination4
SecondaryExpanded Disability Status Scale (EDSS) Score

EDSS is an ordinal scale in half-point increments that qualifies disability in participants with MS. It consists of 8 ordinal rating scales assessing seven functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder and cerebral) as well as ambulation. EDSS total score ranges from 0 (normal neurological examination) to 10 (death due to MS).

Time frame:
Baseline, Month 12
Reported as:
Mean · Units on a scale
Expanded Disability Status Scale (EDSS) Score
Units on a scaleRebif In RMS SubjectsRebif in CIS Subjects
Baseline1.87 ± 0.9911.24 ± 0.615
Month 121.80 ± 0.9811.13 ± 0.581
SecondaryBody Mass Index (BMI)

BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2).

Time frame:
Baseline, Month 12
Reported as:
Mean · Kg/m^2
Body Mass Index (BMI)
Kg/m^2Rebif In RMS and CIS Subjects
Baseline23.57 ± 3.347
Month 1223.51 ± 3.582

Adverse events

Collected over Baseline up to 12 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rebif—1/106 (0.9%)15/106 (14.2%)
Most frequent serious events
Most frequent serious events
EventRebif
DepressionPsychiatric disorders1/106
Most frequent other events
Most frequent other events
EventRebif
Influenza Like IllnessGeneral disorders9/106
Hepatic Enzyme IncreasedInvestigations7/106

Baseline characteristics

Full analysis set included all subjects enrolled into the study and who received at least one dose of study treatment.

Age, Continuous
Age, Continuous(years)Rebif In RMS SubjectsRebif in CIS SubjectsTotal
Mean36.1 ± 10.7131.6 ± 9.6335.4 ± 10.64
Sex: Female, Male
Sex: Female, Male(Participants)Rebif In RMS SubjectsRebif in CIS SubjectsTotal
Female58765
Male311041
Number of Subjects Living in City or Rural Area
Number of Subjects Living in City or Rural Area(subjects)Rebif In RMS SubjectsRebif in CIS SubjectsTotal
City711384
Rural18422
Geographical Allocation
Geographical Allocation(subjects)Rebif In RMS SubjectsRebif in CIS SubjectsTotal
North eastern18321
North western23326
South eastern451055
South western314
Nicotine Used Status
Nicotine Used Status(subjects)Rebif In RMS SubjectsRebif in CIS SubjectsTotal
Never used631073
Regular user19322
Occasional user000
Former user7411
Alcohol Consumption
Alcohol Consumption(subjects)Rebif In RMS SubjectsRebif in CIS SubjectsTotal
Subjects consumed alcohol314
Subjects did not consume alcohol8616102
08

Study locations

1 site
  • Please contact the Merck KGaA Communication Center
    Darmstadt, Germany
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2014 to primary completion in Aug 2016, 19 months.

Results were first posted in Mar 2018, 1 year 7 months after primary completion.

Of 36 industry-sponsored phase 4 interventional studies under Multiple Sclerosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 37. This study's 19 months is below that.

Counting every sponsor, half of 69 studies reached it within 34 months; a quarter within 23 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2014
First posted
Oct 1, 2014
StartActual
Dec 31, 2014
Primary completionActual
Aug 20, 2016
CompletionActual
Aug 20, 2016
Results first posted
Mar 30, 2018
Last update
Mar 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02254304
Collaborators
Merck Romania SRL, an affiliate of Merck KGaA, Darmstadt, Germany
Responsible party
Sponsor
First posted
Oct 1, 2014
Start date
Dec 31, 2014
Primary completion
Aug 20, 2016
Completion
Aug 20, 2016
Results posted
Mar 30, 2018
Last update
Mar 30, 2018

Study contacts

Medical Responsible
study director · Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interferon beta-1a

Start the discussion